1. Please check and comment entries here.
Table of Contents

    Topic review

    Radiotherapy for Sinonasal Malignant Tumors

    Subjects: Oncology
    View times: 3
    Submitted by: Juliette THARIAT


    Radiotherapy plays an important role in the treatment of sinonasal cancer, mainly in the adjuvant setting after surgical resection. Many technological approaches have been described, including intensity-modulated radiotherapy, concomitant chemoradiotherapy, charged particle therapy or combined approaches. The choice is based on general criteria related to the oncological results and morbidity of each technique and their availability, as well as specific criteria related to the tumor (tumor extensions, pathology and quality of margins).

    1. Introduction

    Sinonasal neoplasms represent 3% of head and neck cancers and a yearly incidence of 1/100,000 inhabitants in France. The paranasal sinuses harbor a wide variety of histologically distinct neoplasms. There are complex anatomical structures that lie in close proximity to critical structures such as optic nerves, orbits and their content (eye-ball, oculomotor muscles and nerves), optic chiasm, pituitary gland, internal carotid artery, cranial nerves and brain. The paranasal sinuses are characterized by a complex shape, air-soft tissues/mucosae-bone interfaces and are variably filled in with secretions. These characteristics are of special relevance for surgery and postoperative radiotherapy.
    The majority of sinonasal neoplasms are very aggressive with 5-year survival rates of 30–60% and local recurrence as the main cause of death, but their patterns of spread and response rates to chemo- and radiotherapy vary widely [1][2]. Sinonasal neoplasms as well as the treatment of these neoplasms can lead to altered olfaction, taste, respiration, speech, vision and cosmesis. The REFCOR (Reseau d’Expertise Francais des Cancers ORL Rares) and EURACAN (European reference network for rare adult solid cancers) networks have been dedicated to improving the diagnosis and therapeutic management of sinonasal neoplasms for more than 2 decades and since 2011 for the International Rare Cancer Initiative (IRCI).
    In contrast to conventional sites (pharynx and oral cavity), histologic subtypes are more varied. Squamous cell carcinomas represent 50% of sinonasal sites, intestinal-type adenocarcinomas (ITAC) 13%, mucosal melanomas 7%, olfactive neuroblastomas 7%, adenoid cystic carcinomas 7%, undifferentiated carcinomas 3% and other histologies 13% [2][3]. Oncologic outcomes also vary according to the pathology: 5-year survival rates are 50% for squamous cell carcinomas, 60% for ITAC, 30% for melanomas, 70% for olfactive neuroblastomas, 70% for adenoid cystic carcinomas and neuroendocrine carcinomas and 35% for undifferentiated carcinomas. Local relapse is the dominant pattern of failure for all histologies except melanomas, which mostly fail distantly. For example, crude local relapse rates of sinonasal squamous cell carcinomas yield 40% (5-year local failure rate of 50%), of which less than 20% are efficiently salvaged [4], and ipsilateral level Ib-IIa and upper retropharyngeal nodes are common failure sites for T3–4 cases.
    Due to the non-specific symptoms, sinonasal tumors are often diagnosed late with locally advanced disease. While surgery is the mainstay of treatment in all histologies, achieving wide surgical resection with clear margins is a challenge. Resection is feasible in about 75% of sinonasal neoplasms [5][6] and only 53% of sinonasal squamous cell carcinomas [7][8]. Radiotherapy is thus usually indicated as a definitive exclusive treatment (generally with concomitant chemotherapy) when tumors are not resectable and as an adjuvant modality following surgery to optimize local control. Sinonasal tumors are indeed an example of multidisciplinarity and should be best performed at high volume centers [8][9] (Figure 1). The multidimensionality of the decision-making process is best demonstrated in borderline situations. Of those, orbital preservation best represents the compromise made to achieve acceptable oncological results while maximizing functional outcomes [10]. For example, induction chemotherapy and endoscopic-assisted surgery allowed orbital preservation in 76.6% of sinonasal squamous cell carcinomas; 96.0% of patients treated using an orbit-sparing approach maintained a functional eye after treatment [10].
    Figure 1. Prerequisite for adjuvant radiotherapy planning in sinonasal carcinomas. Legend: importance of time between surgery and radiotherapy on tumor control; RO: radiation oncologist.

    2. Radiotherapy

    2.1. Indication and Techniques

    Patients with contraindications to surgery, either due to patient or tumor resectability, should receive Radiotherapy with multidisciplinary discussion of concomittant cisplatin owing to the weak level of evidence in this situation. In the postoperative setting, all patients, except those with pT1 tumors involving the infrastructure only and with negative margins [11], benefit from adjuvant radiotherapy with differential magnitude of benefit across histologies [2]. Data are lacking after endoscopic surgery to modify expert recommendation based on mostly retrospective series [2][12]; furthermore, definition of margin is less clear with endoscopic procedures, and tumor dissemination may sometimes be an issue when en bloc resection cannot be achieved. Altogether, waiting for available new data reinforces the indication of adjuvant radiotherapy post endoscopic surgery with the same indication as that of a post open surgery.
    Local control is dose-dependent (requiring 60–66 Gy) but technically challenging due to close proximity of critical organs and accompanying toxicity (which is also dose-dependent with dose > 45 Gy).
    Technological advances have made minimally morbid radiotherapy possible. Integration of computer science in radiotherapy and advanced linear accelerator technologies in the 1990s have led to more conformal radiotherapy, i.e., intensity-modulated radiotherapy (IMRT). This has been achieved by means of computer- and multi-leaf collimator-guided photon fluence modulation to achieve steep dose gradients. The IMRT transition was primarily driven by the improvement in radiation dose distribution with IMRT compared to conventional two-dimensional (2D) and tridimensional conformal (3D) techniques [13]. As IMRT enables delivery of adequate doses to sinonasal tumors [14] while minimizing the dose to nearby critical organs [15], benefits in terms of local control and toxicities were expected, and this technique became the standard of care.
    Charged particle therapy, which includes definitive/postoperative proton therapy (or definitive carbon ion therapy), is another recognized technique for the treatment of sinonasal neoplasms [16], but available machines remain rare.

    2.2. Local Control with IMRT

    With IMRT, 2- and 5-year local control rates are in the order of 80% and 50–70% for sinonasal tumors undergoing postoperative radiotherapy (+/−20% depending on histology) [17][18][19]. Most series are retrospective and consist of 50–200 patients. IMRT (including volumetric arc therapy) has consistently shown better 3-year locoregional recurrence-free survival rates by 20–30% compared with 3D conformal RT for carcinomas (89% vs. 60%; p = 0.035 [13], 85% vs. 65%, p = 0.02) [18][20]. For inoperable T4 paranasal sinus and skull-base tumors, the steep dose-gradient between tumor and normal tissue is even more advantageous, given the crucial need to maintain dose intensity to the tumor [21]. Some series also suggest improved survival with IMRT (60% vs. 72%; p = 0.02) while minimizing toxicities [22].

    2.3. Toxicities Induced by IMRT

    Similar or lower rate of acute toxicities not reaching significance have been observed with IMRT compared to 3D radiotherapy [20]. Fewer [6] (by about 20% compared with 3D radiotherapy) or less severe late toxicities have been reported [18][20]. Severe late radiation-induced toxicities have decreased in rate from about 50% of patients in the 1960s, 35–40% in the 1980s, and 15% in the 2000s and severe (grade 3+) to less debilitating (grade 2 or higher), yet bothersome symptoms. Historical series of conventional radiotherapy showed unilateral visual loss of up to 64% and bilateral blindness of about 2% [23]. IMRT significantly reduces the high doses to optic structures [24]. Subsequently, early IMRT studies showed major reduction of toxicities. While early IMRT series may have underestimated toxicity rates [25][26][27][28][29], other series report grade ≥ 2 late toxicities in the order of 28% [18]. Grade 2+ visual deterioration is reported in about 12–20% of patients [18][20][30][31][32]; 63% impaired olfactory function [32]; ear loss in 8–46% [5][33][34]); hormonal deficiencies in 22–62% including hypopituitarism in 24% [32][35]; cognitive dysfunction in up to 77% affecting short-term memory and speech; and fatigue in 18% [36][37]. According to Hamilton et al., sinonasal neoplasms are associated with significant symptoms during RT including pain, mucositis and dysgeusia [38].
    Dose-response associations have been found between visual acuity impairment and the optic nerve and between fatigue and the temporal lobes after IMRT for sinonasal cancer but not for hypopituitarism or impaired olfactory function [32][39], possibly due to prescription dose to tumor nearby exceeding threshold dose for the given organ. Moreover, 11% of patients had structural abnormalities in irradiated areas of the brain, and impaired cognitive function was present in 63% of patients. Limited experience also suggests that quality of life (QoL) may return to pretherapeutic levels after 12 months using IMRT [18]. Impaired cognitive function as well as fatigue and insomnia were affected the most in QoL analyses [32]. Grade 3+ toxicity seems to be more likely in T4 tumors in relation to tumor stage and extensions, where compromise on tumor control may not be acceptable [18][32]. However, there seems to exist some latitude to apply stronger dose constraints to organs without jeopardizing tumor control [32].
    Currently, the postoperative bed is usually irradiated at a similar high dose level without modulation on piecemeal analysis. IMRT may further allow selective dose escalation of RT to further improve outcomes. It is therefore advisable to better define, thanks to the clinico-radiological pair, the sinonasal subunits invaded by the tumor. In the meantime, some anatomical structures, for instance, involved in swallowing as late radiation-associated dysphagia, may often occur [12][40], which can be spared by dose reduction.

    2.4. Toxicities Induced by Proton Therapy or Charged Particle Therapy

    Charged particle therapy may better spare the organs at risk than IMRT [19][41][42][43][44] or may be used as an adjunct [34]. Despite increased sensitivity to anatomy, tumor and cavity filling change during radiotherapy of sinonasal neoplasms with protons versus photons, and organs at risk appear to receive smaller doses with proton therapy than IMRT [45] using adaptive replanning [46]. This is, however, dependent on the extent and bilaterality of tumors and may be best assessed by provisional dosimetry. Moreover, one risk of extreme conformality is geometric miss and unusual local relapse by unintentional sparing of tumor spread pathways (excess of leptomeningeal relapses have been observed after proton therapy due to better brain/meningeal sparing) [43][47].
    Similar trends are observed with passive scattering compared multifield-optimized intensity-modulated proton therapy (IMPT) [19]. Limited experience with IMPT suggests that 24% experienced acute grade 3 toxicities, and 6% experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis and soft tissue fibrosis) [19]. Complication probability modelling (NTCP) can be used to inform patients of their likely outcomes.

    This entry is adapted from 10.3390/cancers13194802


    1. Gore, M.R.; Zanation, A.M. Survival in Sinonasal Melanoma: A Meta-analysis. J. Neurol. Surg. B Skull Base 2012, 73, 157–162.
    2. Thariat, J.; Moya Plana, A.; Verillaud, B.; Vergez, S.; Regis-Ferrand, F.; Digue, L.; Even, C.; Costes, V.; Baujat, B.; de Gabory, L.; et al. Diagnosis, prognosis and treatment of sinonasal carcinomas (excluding melanomas, sarcomas and lymphomas). Bull. Cancer 2020, 107, 601–611.
    3. Slevin, F.; Pan, S.; Mistry, H.; Denholm, M.; Shor, D.; Oong, Z.; Price, J.; Jadon, R.; Fleming, J.C.; Barnett, G.; et al. A Multicentre UK Study of Outcomes for Locally Advanced Sinonasal Squamous Cell Carcinoma Treated with Adjuvant or Definitive Intensity-modulated Radiotherapy. Clin. Oncol. 2021, 33, e450–e461.
    4. Mirghani, H.; Mortuaire, G.; Armas, G.L.; Hartl, D.; Auperin, A.; El Bedoui, S.; Chevalier, D.; Lefebvre, J.L. Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases. Head Neck 2014, 36, 667–674.
    5. Owin, N.; Elsayad, K.; Rolf, D.; Haverkamp, U.; Suwelack, D.; Tschakert, R.; Berssenbrugge, H.; Kleinheinz, J.; Rudack, C.; Eich, H.T. Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies. Anticancer Res. 2021, 41, 1587–1592.
    6. Laskar, S.G.; Pai, P.; Sinha, S.; Budrukkar, A.; Nair, D.; Swain, M.; Mummudi, N.; Gupta, T.; Murthy, V.; Agarwal, J.P.; et al. Intensity-modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute. Head Neck 2021, 43, 2045–2057.
    7. Shay, A.; Ganti, A.; Raman, A.; Kuhar, H.N.; Auger, S.R.; Eggerstedt, M.; Patel, T.; Kuan, E.C.; Batra, P.S.; Tajudeen, B.A. Survival in low-grade and high-grade sinonasal adenocarcinoma: A national cancer database analysis. Laryngoscope 2019, 130, E1–E10.
    8. Teitelbaum, J.I.; Issa, K.; Barak, I.R.; Ackall, F.Y.; Jung, S.H.; Jang, D.W.; Abi Hachem, R. Sinonasal Squamous Cell Carcinoma Outcomes: Does Treatment at a High-Volume Center Confer Survival Benefit? Otolaryngol. Head Neck Surg. 2020, 163, 986–991.
    9. Pare, A.; Blanchard, P.; Rosellini, S.; Auperin, A.; Gorphe, P.; Casiraghi, O.; Temam, S.; Bidault, F.; Page, P.; Kolb, F.; et al. Outcomes of multimodal management for sinonasal squamous cell carcinoma. J. Craniomaxillofac. Surg. 2017, 45, 1124–1132.
    10. Turri-Zanoni, M.; Lambertoni, A.; Margherini, S.; Giovannardi, M.; Ferrari, M.; Rampinelli, V.; Schreiber, A.; Cherubino, M.; Antognoni, P.; Locatelli, D.; et al. Multidisciplinary treatment algorithm for the management of sinonasal cancers with orbital invasion: A retrospective study. Head Neck 2019, 41, 2777–2788.
    11. Lund, V.J.; Clarke, P.M.; Swift, A.C.; McGarry, G.W.; Kerawala, C.; Carnell, D. Nose and paranasal sinus tumours: United Kingdom National Multidisciplinary Guidelines. J. Laryngol. Otol. 2016, 130, S111–S118.
    12. NCCN. National Comprehensive Cancer Network. Head Neck Cancers. 2021. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437 (accessed on 19 August 2021).
    13. Suh, Y.G.; Lee, C.G.; Kim, H.; Choi, E.C.; Kim, S.H.; Kim, C.H.; Keum, K.C. Treatment outcomes of intensity-modulated radiotherapy versus 3D conformal radiotherapy for patients with maxillary sinus cancer in the postoperative setting. Head Neck 2016, 38 (Suppl. 1), E207–E213.
    14. Huang, D.; Xia, P.; Akazawa, P.; Akazawa, C.; Quivey, J.M.; Verhey, L.J.; Kaplan, M.; Lee, N. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56, 158–168.
    15. Cheng, Y.F.; Lai, C.C.; Ho, C.Y.; Shu, C.H.; Lin, C.Z. Toward a better understanding of sinonasal mucosal melanoma: Clinical review of 23 cases. J. Chin. Med. Assoc. 2007, 70, 24–29.
    16. Patel, S.H.; Wang, Z.; Wong, W.W.; Murad, M.H.; Buckey, C.R.; Mohammed, K.; Alahdab, F.; Altayar, O.; Nabhan, M.; Schild, S.E.; et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: A systematic review and meta-analysis. Lancet Oncol. 2014, 15, 1027–1038.
    17. Askoxylakis, V.; Hegenbarth, P.; Timke, C.; Saleh-Ebrahimi, L.; Debus, J.; Roder, F.; Huber, P.E. Intensity modulated radiation therapy (IMRT) for sinonasal tumors: A single center long-term clinical analysis. Radiat. Oncol. 2016, 11, 1–9.
    18. Al-Mamgani, A.; Monserez, D.; Rooij, P.; Verduijn, G.M.; Hardillo, J.A.; Levendag, P.C. Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol. 2012, 48, 905–911.
    19. Fan, M.; Kang, J.J.; Lee, A.; Fan, D.; Wang, H.; Kitpanit, S.; Fox, P.; Sine, K.; Mah, D.; McBride, S.M.; et al. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer 2020, 126, 1905–1916.
    20. Frederic-Moreau, T.; Piram, L.; Bellini, R.; Martin, F.; Miroir, J.; Saroul, N.; Pham Dang, N.; Lapeyre, M.; Biau, J. Postoperative volumetric modulated arc therapy for sinonasal cancer: Improved survival compared with 3D conformal radiation therapy. Head Neck 2019, 41, 448–455.
    21. Liang, Z.G.; Kusumawidjaja, G.; Kazmi, F.; Wee, J.T.S.; Chua, M.L.K. Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. Oral Oncol. 2018, 86, 61–68.
    22. Dirix, P.; Vanstraelen, B.; Jorissen, M.; Vander Poorten, V.; Nuyts, S. Intensity-modulated radiotherapy for sinonasal cancer: Improved outcome compared to conventional radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78, 998–1004.
    23. Chi, A.; Nguyen, N.P.; Tse, W.; Sobremonte, G.; Concannon, P.; Zhu, A. Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation. J. Hematol. Oncol. 2013, 6, 1–10.
    24. Thariat, J.; Racadot, S.; Pointreau, Y.; Boisselier, P.; Grange, J.D.; Graff, P.; Weber, D.C. Intensity-modulated radiotherapy of head and neck cancers: Dose effects on the ocular, orbital and eyelid structures. Cancer Radiother. 2016, 20, 467–474.
    25. Combs, S.E.; Konkel, S.; Schulz-Ertner, D.; Munter, M.W.; Debus, J.; Huber, P.E.; Thilmann, C. Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: Clinical benefit for complex shaped target volumes. Radiat. Oncol. 2006, 1, 1–8.
    26. Combs, S.E.; Konkel, S.; Thilmann, C.; Debus, J.; Schulz-Ertner, D. Local high-dose radiotherapy and sparing of normal tissue using intensity-modulated radiotherapy (IMRT) for mucosal melanoma of the nasal cavity and paranasal sinuses. Strahlenther. Onkol. 2007, 183, 63–68.
    27. Chen, A.M.; Daly, M.E.; El-Sayed, I.; Garcia, J.; Lee, N.Y.; Bucci, M.K.; Kaplan, M.J. Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 338–343.
    28. Daly, M.E.; Chen, A.M.; Bucci, M.K.; El-Sayed, I.; Xia, P.; Kaplan, M.J.; Eisele, D.W. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 151–157.
    29. Wiegner, E.A.; Daly, M.E.; Murphy, J.D.; Abelson, J.; Chapman, C.H.; Chung, M.; Yu, Y.; Colevas, A.D.; Kaplan, M.J.; Fischbein, N.; et al. Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: Clinical outcomes and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, 243–251.
    30. Batth, S.S.; Sreeraman, R.; Dienes, E.; Beckett, L.A.; Daly, M.E.; Cui, J.; Mathai, M.; Purdy, J.A.; Chen, A.M. Clinical-dosimetric relationship between lacrimal gland dose and ocular toxicity after intensity-modulated radiotherapy for sinonasal tumours. Br. J. Radiol. 2013, 86, 20130459.
    31. Duthoy, W.; Boterberg, T.; Claus, F.; Ost, P.; Vakaet, L.; Bral, S.; Duprez, F.; Van Landuyt, M.; Vermeersch, H.; De Neve, W. Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: Clinical results in 39 patients. Cancer 2005, 104, 71–82.
    32. Sharma, M.B.; Jensen, K.; Urbak, S.F.; Funding, M.; Johansen, J.; Bechtold, D.; Amidi, A.; Eskildsen, S.F.; Jorgensen, J.O.L.; Grau, C. A multidimensional cohort study of late toxicity after intensity modulated radiotherapy for sinonasal cancer. Radiother. Oncol. 2020, 151, 58–65.
    33. Huang, T.L.; Chien, C.Y.; Tsai, W.L.; Liao, K.C.; Chou, S.Y.; Lin, H.C.; Dean Luo, S.; Lee, T.F.; Lee, C.H.; Fang, F.M. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck 2016, 38 (Suppl. 1), E1026–E1032.
    34. Dautruche, A.; Bolle, S.; Feuvret, L.; Le Tourneau, C.; Jouffroy, T.; Goudjil, F.; Zefkili, S.; Nauraye, C.; Rodriguez, J.; Herman, P.; et al. Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy. Cancer Radiother. 2018, 22, 411–416.
    35. Snyers, A.; Janssens, G.O.; Twickler, M.B.; Hermus, A.R.; Takes, R.P.; Kappelle, A.C.; Merkx, M.A.; Dirix, P.; Kaanders, J.H. Malignant tumors of the nasal cavity and paranasal sinuses: Long-term outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1343–1351.
    36. Bossi, P.; Di Pede, P.; Guglielmo, M.; Granata, R.; Alfieri, S.; Iacovelli, N.A.; Orlandi, E.; Guzzo, M.; Bianchi, R.; Ferella, L.; et al. Prevalence of Fatigue in Head and Neck Cancer Survivors. Ann. Otol. Rhinol. Laryngol. 2019, 128, 413–419.
    37. Ferris, M.J.; Zhong, J.; Switchenko, J.M.; Higgins, K.A.; Cassidy, R.J., 3rd; McDonald, M.W.; Eaton, B.R.; Patel, K.R.; Steuer, C.E.; Baddour, H.M., Jr.; et al. Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy. Radiother. Oncol. 2018, 126, 100–106.
    38. Hamilton, S.N.; Tran, E.; Ho, C.; Berthelet, E.; Wu, J.; DeVries, K.; LaPointe, V.; Bowman, A.; Lagman, M.; Olson, R. Patient-reported outcome measures in patients undergoing radiotherapy for head and neck cancer. Support. Care Cancer 2021, 29, 2537–2547.
    39. Gulliford, S.L.; Miah, A.B.; Brennan, S.; McQuaid, D.; Clark, C.H.; Partridge, M.; Harrington, K.J.; Morden, J.P.; Hall, E.; Nutting, C.M. Dosimetric explanations of fatigue in head and neck radiotherapy: An analysis from the parsport Phase III trial. Radiother. Oncol. 2012, 104, 205–212.
    40. Schreiber, A.M.; Dawson, C.; Skoretz, S.A. Late Dysphagia Following Radiotherapy After Nasopharyngeal Carcinoma: A Case Series. Am. J. Speech Lang. Pathol. 2020, 29, 319–326.
    41. Hakansson, K.; Smulders, B.; Specht, L.; Zhu, M.; Friborg, J.; Rasmussen, J.H.; Bentzen, S.M.; Vogelius, I.R. Radiation dose-painting with protons vs. photons for head-and-neck cancer. Acta Oncol. 2020, 59, 525–533.
    42. Yu, N.Y.; Gamez, M.E.; Hartsell, W.F.; Tsai, H.K.; Laramore, G.E.; Larson, G.L.; Simone, C.B., 2nd; Rossi, C.; Katz, S.R.; Buras, M.R.; et al. A Multi-Institutional Experience of Proton Beam Therapy for Sinonasal Tumors. Adv. Radiat. Oncol. 2019, 4, 689–698.
    43. Orlandi, E.; Iacovelli, N.A.; Cavallo, A.; Resteghini, C.; Gandola, L.; Licitra, L.; Bossi, P. Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression? Head Neck 2019, 41, 3733–3735.
    44. Toyomasu, Y.; Demizu, Y.; Matsuo, Y.; Sulaiman, N.S.; Mima, M.; Nagano, F.; Terashima, K.; Tokumaru, S.; Hayakawa, T.; Daimon, T.; et al. Outcomes of Patients With Sinonasal Squamous Cell Carcinoma Treated With Particle Therapy Using Protons or Carbon Ions. Int. J. Radiat. Oncol. Biol. Phys. 2018, 101, 1096–1103.
    45. Narita, Y.; Kato, T.; Ono, T.; Oyama, S.; Komori, S.; Arai, K.; Abe, Y.; Harada, T.; Nakamura, T.; Wada, H.; et al. Effect of anatomical change on dose distribution during radiotherapy for maxillary sinus carcinoma: Passive scattering proton therapy versus volumetric-modulated arc therapy. Br. J. Radiol. 2019, 92, 20180273.
    46. Nenoff, L.; Matter, M.; Hedlund Lindmar, J.; Weber, D.C.; Lomax, A.J.; Albertini, F. Daily adaptive proton therapy—The key to innovative planning approaches for paranasal cancer treatments. Acta Oncol. 2019, 58, 1423–1428.
    47. Dagan, R.; Bryant, C.; Li, Z.; Yeung, D.; Justice, J.; Dzieglewiski, P.; Werning, J.; Fernandes, R.; Pirgousis, P.; Lanza, D.C.; et al. Outcomes of Sinonasal Cancer Treated With Proton Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2016, 95, 377–385.